ArticleBioengineering (Basel, Switzerland)2021
Topical Allopurinol-Loaded Nanostructured Lipid Carriers: A Novel Approach for Wound Healing Management.
Article in Bioengineering (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 24 citations in OpenAlex.
- Nanostructured Lipid Carrier-Gels for Wound Healing: A Narrative Review of Formulation Strategies, Mechanisms, and Translational Potential.Nanotechnology, science and applications · 2026Review
- Curcumin and EGCG combined formulation in nanostructured lipid carriers for anti-aging applications.International journal of pharmaceutics: X · 2025Article
- Current Challenges and Emerging Therapies in the Treatment of Gout.Current rheumatology reviews · 2025Review
- Tissue Regeneration and Remodeling in Rat Models after Application ofGels (Basel, Switzerland) · 2024Article
- Biomaterials Functionalized with Inflammasome Inhibitors-Premises and Perspectives.Journal of functional biomaterials · 2024Review
- Advancements and Challenges of Nanostructured Lipid Carriers for Wound Healing Applications.International journal of nanomedicine · 2024Review
- Intervertebral disk regeneration in a rat model by allopurinol-loaded chitosan/alginate hydrogel.Biomolecules & biomedicine · 2023Article
- Pharmaceutical Characterization andArchives of Razi Institute · 2022Article
- An Update on Advancements and Challenges in Inhalational Drug Delivery for Pulmonary Arterial Hypertension.Molecules (Basel, Switzerland) · 2022Review
- Novel Hydrogels for Topical Applications: An Updated Comprehensive Review Based on Source.Gels (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Nanostructured lipid carriers (NLC) have been widely studied as delivery systems for a variety of routes, including the skin. Their composition results in an imperfect lipid matrix, allowing increased drug encapsulation. Allopurinol (AP), a xanthine oxidase inhibitor, is characterized by low water solubility and high melting point, which has hampered its use through the topical route. In this work, AP was incorporated in a NLC formulation to enhance drug-carrier association and skin delivery as a topical approach to treat wounds. AP-NLC system was characterized in terms of size, charge, rheological behavior, and in vitro skin permeation. The in vitro cytotoxicity was evaluated using HaCaT cells. The wound healing efficacy of the AP-NLC formulation on animal skin lesions was evaluated in male Wistar rats. The AP-NLC presented a mean size of 193 ± 15 nm with a PdI of 0.240 ± 0.02, zeta potential values around -49.6 mV, and an encapsulation efficiency of 52.2%. The AP-NLC formulation presented an adequate profile to be used topically, since epidermal and dermal drug retention were achieved. No reduction in HaCaT cells viability was observed at the tested concentrations (AP < 10 μg/mL). The in vivo application of the AP-NLC formulation resulted in the regeneration of skin lesions when compared with non-treated controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.